PHASE I STUDY OF TRIAPINE IN COMBINATION WITH DOXORUBICIN IN REFRACTORY TUMORS

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。（来自国家癌症研究所PDQ数据库的临床试验总结）化疗中使用的药物，如阿霉素，以不同的方式阻止肿瘤细胞分裂，使它们停止生长或死亡。三羟甲基氨基甲烷（3-AP）可以通过阻断肿瘤细胞生长所必需的酶来阻止肿瘤细胞的生长，并可以通过使多柔比星对药物更敏感来帮助多柔比星杀死更多的癌细胞。 这项I期临床试验正在研究曲拉唑和阿霉素治疗转移性或难治性实体瘤患者的副作用和最佳剂量。 患者将在第1天接受多柔比星输注。他们还将在第1-4天接受2小时的Trilazone输注。治疗可以每3周重复一次，只要显示出益处。将定期对患者进行评估。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (Clinical trial summary from the National Cancer Institute's PDQ database) Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Triapine (3-AP) may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help doxorubicin kill more cancer cells by making them more sensitive to the drug. This phase I trial is studying the side-effects and best dose of triapine and doxorubicin in treating patients with metastatic or refractory solid tumors. Patients will receive an infusion of doxorubicin on Day 1. They will also receive a 2-hour infusion of triapine on Days 1-4. Treatment may be repeated every 3 weeks for as long as benefit is shown. Patients will be evaluated periodically.